Kamada (KMDA) Total Non-Current Liabilities (2012 - 2026)
Kamada's (KMDA) quarterly Total Non-Current Liabilities came in at $64.4 million in Q2 2026, up 3.2% on a YoY basis from $62.4 million in Q2 2025, and up 0.92% quarter-over-quarter from $63.9 million in Q1 2026.
Analysis
Kamada (KMDA) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Total Non-Current Liabilities for 13 consecutive years, with $64.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Total Non-Current Liabilities rose 3.2% year-over-year to $64.4 million; the trailing twelve-month figure through Jun 2026 stood at $64.4 million (up 3.2% YoY), and the FY2025 full-year result was $62.2 million, down 1.82% from the prior year.
- Total Non-Current Liabilities improved to $64.4 million in Q2 2026 per KMDA's latest filing, from $63.9 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $85.7 million in Q1 2022 and bottomed at -$6.3 million in Q4 2022.
- Historically, Total Non-Current Liabilities has averaged $59.6 million across 5 years, with a median of $63.6 million in 2024.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities plunged 530.38% in 2022, then soared 6569.59% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at -$6.3 million in 2022, then soared by 84.36% to -$980000.0 in 2023, then jumped by 6569.59% to $63.4 million in 2024, then retreated by 1.82% to $62.2 million in 2025, then advanced by 3.53% to $64.4 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $64.4 million, $63.9 million, and $62.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.39 Bn | 197.40 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 181.14 Bn | 177.96 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 82.91 Bn | 74.91 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 61.55 Bn | 56.36 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 54.39 Bn | 49.25 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 34.43 Bn | 31.12 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.18 Bn | 29.89 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Roivant Sciences | 30.11 Bn | 30.11 Bn | 1.16 Mn | 378.37 Mn |
| 10 | Kamada | 472.70 Mn | 402.57 Mn | 22.47 Mn | 64.45 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 64.45 Mn |
| Mar 31, 2026 | 63.86 Mn |
| Dec 31, 2025 | 62.25 Mn |
| Sep 30, 2025 | 64.14 Mn |
| Jun 30, 2025 | 62.45 Mn |
| Mar 31, 2025 | 66.10 Mn |
| Dec 31, 2024 | 63.40 Mn |
| Sep 30, 2024 | 61.94 Mn |
| Jun 30, 2024 | 58.99 Mn |
| Mar 31, 2024 | 59.49 Mn |
| Dec 31, 2023 | -980,000.00 |
| Sep 30, 2023 | 61.39 Mn |
| Jun 30, 2023 | 71.81 Mn |
| Mar 31, 2023 | 72.71 Mn |
| Dec 31, 2022 | -6.27 Mn |
| Sep 30, 2022 | 77.94 Mn |
| Jun 30, 2022 | 82.88 Mn |
| Mar 31, 2022 | 85.72 Mn |
| Dec 31, 2021 | -994,000.00 |
| Sep 30, 2021 | 8.33 Mn |